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Abstract 
Extended-spectrum beta-lactamases (ESBLs) are plasmid-mediated beta lactamases commonly found in the 
Enterobacteriaceae that are capable of hydrolysing β-lactams except carbapenems and cephamycins. ESBLs 
confer resistance to several non-ß-lactam antibiotics. ESBL-producing organisms appear susceptible to 
cephalosporins in vitro using conventional breakpoints but ineffective in vivo. This work sought to determine the 
occurrence of ESBL in E. coli and K. pneumoniae and their antibiotic resistance profile. Four hundred K. 
pneumoniae and E. coli non-duplicate isolates were collected at the Central Laboratory of Korle Bu Teaching 
Hospital and Advent Clinical Laboratories. They were definitively identified and their minimum inhibition 
concentration and antibiotic sensitivity testing for 17 antibiotics were determined using Vitek 2 Compact System 
(bioMérieux, Marcy I’Etoile, France).  The isolates were confirmed as ESBL-producing strains using the 
Combination Disk Synergy Method. The results indicated that 202 (50.5%) of the bacterial isolates were ESBL-
producing phenotypes with high resistant to gentamicin, ciprofloxacin, tetracycline and 
trimethoprim/sulfamethoxazole indicating 82.2%, 79.7%, 70.8% and 97% resistant rates respectively. imipenem 
and amikacin were the antibiotics of choice with 99% and 94.1% susceptibility rates (MIC90 of ≤1µg/ml and 
4µg/ml respectively). It is imperative to routinely detect ESBL-phenotypes in health facilities, implement 
appropriate antibiotic administration policy and infection control measures in the hospitals.    
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1.0 Introduction 
Extended-spectrum beta-lactamases (ESBLs) are plasmid-mediated beta lactamases that are capable of 
hydrolysing β-lactams except carbapenems and cephamycins. They are inhibited by β-lactamase inhibitors such 
as clavulanic acid, sulbactam and tazobactam. They have been found in the Enterobacteriaceae and other Gram-
negative bacilli. ESBL producing isolates are predominantly Klebsiella pneumoniae and Escherichia coli 
(Paterson and Bonomo, 2005). The known risk factors for colonization and infection with ESBL producing 
bacteria include admission to an intensive care unit, recent surgery, instrumentation, prolonged hospital stay and 
antibiotic exposure, especially to extended-spectrum beta-lactam antibiotics (Paterson and Bonomo, 2005). The 
use of extended-spectrum antibiotics exerts a selective pressure for emergence of ESBL-producing strains. 
Because ESBL enzymes are plasmid mediated, the genes encoding these enzymes are easily transferable among 
different bacteria. Most of these plasmids not only contain DNA encoding ESBL but also carry genes conferring 
resistance to several non-ß-lactam antibiotics. Consequently, most ESBL isolates are not only resistant to 
penicillins, cephalosporins and monobactams but also to other classes of antibiotics including aminoglycosides, 
fluoroquinolones, tetracyclines, nitrofurantoin and sulfamethoxazole-trimethoprim. Treatment of these multiple 
drug-resistant organisms has proven to be a therapeutic challenge (Todar, 2008). ESBL-producing isolates pose 
serious public health, financial and logistics challenges because of the limited choice of antibiotics for the 
treatment of infections by ESBL producing isolates. A failure to detect ESBLs and subsequent treatment with 
oxyimino-cephalosporins are associated with a higher risk of therapy failure (Paterson et al., 2001). Other reports 
also indicate higher mortality rates (Kim et al., 2002). This work determined phenotypic occurrence of ESBLs in 
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2.0 Materials and Methods 
2.1 Materials 
Glycerol broth, blood agar and MacConkey agar were prepared according to manufacturers’ guidelines.  MAST 
IDTM ESβL Detection Discs (Mast Group, UK) were used for ESBL screening and confirmation according to 
CLSI standards.  Vitek 2 Compact System (bioMérieux, Marcy I’Etoile, France) was used to identify the 
isolates, determine minimum inhibition concentration of selected antibiotics and interpret the MICs according to 
CSLI breakpoints.  
2.2 Study Sites 
Lactose fermenting bacterial isolates were collected from the Central Laboratory of the Korle Bu Teaching 
Hospital (KBTH) and Advent Clinical Laboratories; both in the Accra Metropolis, Ghana. KBTH is the leading 
national referral centre for estimated 24 million people in Ghana Advent Clinical Laboratory is a private clinical 
laboratory with the state-of-the-art clinical diagnostic equipment located in Dzorwulu in Accra. 
2.3 Sample Size 
A sample size of 400 K. pneumoniae and E. coli corresponds with the standard techniques used to calculate the 
minimum sample size based on the expected prevalence and using appropriate levels of precision at 95% 
confidence level.  
2.4 Inclusion Criteria 
Non-duplicate pure cultures of K. pneumoniae and E. coli were used in the work. 
2.5 Exclusion Criteria 
All isolates not confirmed as K. pneumoniae and E. coli as well as all duplicate cultures was excluded. 
2.6 Identification of Bacterial Isolates, Determination of Minimal Inhibition Concentration (MIC) and Antibiotic 
Sensitivity Testing 
The lactose fermenting bacterial isolates stored in glycerol broth were sub-cultured on blood and MacConkey 
agar and incubated at 35°C for 24 hours. The pure colonies were gram-stained to confirm their Gram negative 
reaction. The isolates were identified as K. pneumoniae and E. coli based on their Gram stain reaction and 
biochemical reaction characteristics using Vitek 2 system.  The Vitek 2 system uses the micro-dilution method to 
determine the MICs of the antibiotics. The 17 antibiotics used were ampicillin, amoxicillin/clavulanic acid, 
piperacillin, piperacillin/tazobactam, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, imipenem, 
amikacin, gentamicin, ciprofloxacin, norfloxacin, tetracycline, nitrofurantoin, trimethoprim/ sulfamethoxazole. 
The Vitek 2 system (bioMérieux, Marcy I’Etoile, France) performs antimicrobial sensitivity testing (AST) based 
on kinetic analysis of growth data. The therapeutic significance of the MIC of the antimicrobials was determined 
using the Vitek 2 Compact system. At the end of the incubation cycle, MIC values and their interpretations 
(susceptible, resistant and indeterminate) were generated for each antibiotic.  
2.7 Detection of ESBL Phenotype using ESBL Screening and Combined Disc Synergy Method 
MAST IDTM ESβL Detection Discs (Mast Group, UK) were used to screen and confirm the ESBL phenotypes. 
The MAST IDTM ESβL Detection Discs comprise of cefpodoxime 30µg disks, cefpodoxime 30µg + clavulanic 
acid 10µg  
disks; ceftazidime 30µg disks, ceftazidime 30µg + clavulanic acid 10µg disks and cefotaxime 30µg disks, 
cefotaxime 30µg + clavulanic acid 10µg disks.  
Using a pure culture of the test organism, a suspension in distilled water equivalent in density to a McFarland 0.5 
opacity standard was prepared. Using a sterile swab, the suspension was spread uniformly across the surface of 
Mueller-Hinton agar plate. Using a sterile forceps, one of each MAST IDTM ESβL Detection Discs was placed 
onto the inoculated medium ensuring that they were evenly spaced. The plates were incubated aerobically at 35-
37°C for 18 – 20 hours. The diameter of any zones of inhibition that were observed were measured and recorded. 
The zone of inhibition for the cefpodoxime, ceftazidime and cefotaxime was compared to that of the 
cefpodoxime, ceftazidime and cefotaxime plus clavulanic acid combination disks. An increase in zone diameter 
of ≥5mm in the presence of clavulanic acid from any or all of the sets of MAST IDTM ESβL Detection Discs 
indicates the presence of ESBL in the test organism. 
2.8 Statistical Analyses 
The data from the work was collated and statistically analysed using one-way analysis of variance (ANOVA)      
. Results were considered significant if p<0.05. 
 
3.0 Results 
3.1 Bacterial Isolates 
Table 1 indicates the distribution of the clinical isolates; 175 were K. pneumoniae and 225 were E. coli.  
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Table 1:                   Number of Bacterial Isolates  
                       K. pneumoniae                   E. coli                        Total 
                      
                          175 (43.7%)                     225 (56.3%)            400 (100%) 
 
3.2 ESBL Producing Phenotypes 
The combined disc synergy method (CDM) detected 202 (50.5%) of ESBL producers among the 400 total 
bacterial isolates of which 130 (74.3%) of the 175 K. pneumoniae and 73 (32.4%) of the 225 E. coli isolates 
were ESBL producers as shown in table 2. There was a significant difference (p<0.05) between the ESBL 
phenotypes detected in the K. pneumoniae and E. coli isolates. 
 
Table 2:      Occurrence of ESBL-producing Phenotypes                        
                                                                          Number (%) 
       ESBL Detection Method     K. pneumoniae      E. coli        All Isolates    
                                                       n=175                 n=225            n=400 
      CDM                                    129(73.7)             73(32.4)        202(50.5)              
         
      CDM: Combined Disk Synergy Method 
 
 
3.3 Antimicrobial Susceptibility among ESBL-producing Isolates 
The percentage antimicrobial susceptibility profile, MIC50 and MIC90 of ampicillin, amoxicillin/clavulanic, 
piperacillin, piperacillin/tazobactam, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, imipenem, 
amikacin, gentamicin, ciprofloxacin, norfloxacin, tetracycline, nitrofurantoin and trimethoprim/sulfamethoxazol 
are indicated in table 3 and figure 1.                         
 
Table 3:       Antimicrobial Susceptibility among ESBL Producers  
Antimicrobial Agent           No.(%) of Susceptible Isolates                        MIC (µg/ml) 
ESBL-phenotypes(n=202)                                  Breakpoint Range            MIC50   MIC90 
                                                                                                                
S      I      R 
 
*Ampicillin                                       0(0.0)  ≤2 16  ≥ 32    ***    ***                       
Amoxicillin/Clavulanic acid            23(11.4)      ≤2 16 ≥ 32     4     8                                      
*Piperacillin                                       0(0.0)           ≤4 32-64  ≥128       ***    ***                          
Piperacillin/Tazobactam                  64(31.7)    ≤4 32  ≥128        8        16   
Cefoxitin                                        149(73.8)   ≤4 16  ≥ 64               ≤ 4        8 
*Cefazolin                                          0(0.0)       ≤4 16  ≥ 64     ***    *** 
*Cefotaxime                                       0(0.0)       ≤1 16  ≥ 64     ***    *** 
*Ceftazidime                                      0(0.0)       ≤1 16  ≥ 64     ***    ***                  
*Cefepime                                          0(0.0)       ≤1 16  ≥ 64               ***    *** 
 Imipenem                                       200(99.0)     ≤1 8  ≥ 16    ≤ 1        ≤ 1                
Amikacin                                         190(94.1)     ≤2  32  ≥  64            ≤ 2         4                                
Gentamicin                                      37(18.3)      ≤1  8   ≥ 16              ≤ 1         2                                          
Ciprofloxacin                                  37(18.3)      ≤0.25  2  ≥ 4            0.5          1  
Norfloxacin                                     42(20.8)      ≤0.5  8  ≥ 16            2     2                   
Tetracycline                                    37(18.3)      ≤1 8  ≥ 16                 ≤ 1         4                                            
Nitrofurantoin                                 73(36.1)       ≤16  64  ≥512          ≤ 16       32                                                      
Trimethoprim/Sulfamethoxazole    5(2.5)       ≤20 80  ≥320           ≤20        ≤20         
MIC50: MIC at which 50% of the ESBL-phenotypes were susceptible to a particular antimicrobial agent        
MIC90: MIC at which 90% of the ESBL-phenotypes were susceptible to a particular antimicrobial agent                                 
*All Penicillins and Cephalosporins are considered resistant to ESBL producers according to CLSI. 
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Figure 1: Antimicrobial Susceptibility among ESBL-Producers 
 
Table 4. MIC of Penicillins and Cephalosporins in Susceptible Ranges among ESBL-Producers  
Antimicrobial Agent           N (%) in Susceptible Ranges                 MIC (µg/ml) 
ESBL-phenotypes (n=202)                               Breakpoint Range    MIC50   MIC90 
                                                                                                                
       S      I      R 
Ampicillin                                        0(0.0)  ≤2 16  ≥ 32     ***    ***    
Piperacillin                                       0(0.0)           ≤4 32-64  ≥128        ***    ***                            
Cefazolin                                          5(2.5)       ≤4 16  ≥ 64    8               8 
Cefotaxime                                       5(2.5)       ≤1 16  ≥ 64    ≤1            ≤1 
Ceftazidime                                      27(13.4)       ≤1 16  ≥ 64              4               4              
Cefepime                                          152(75.3)       ≤1 16  ≥ 64               2               8 
MIC50: MIC at which 50% of the ESBL-phenotypes were in the susceptible ranges to a particular antimicrobial 
agent        
MIC90: MIC at which 90% of the ESBL-phenotypes were in the susceptible ranges to a particular antimicrobial 
agent                                 
3.4 Antimicrobial Resistance among ESBL-producing Isolates 
The percentage antimicrobial resistance profile, MIC50 and MIC90 of ampicillin, amoxicillin/clavulanic, 
piperacillin, piperacillin/tazobactam, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, imipenem, 
amikacin, gentamicin,  
Ciprofloxacin, norfloxacin, tetracycline, nitrofurantoin and trimethoprim/sulfamethoxazole are indicated in table 
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Table 5.           Antimicrobial Resistance among ESBL-Producers  
Antimicrobial Agent             No.(%) of Resistant Isolates                MIC (µg/ml) 
ESBL-phenotypes (n=202)                          Breakpoint Range        MIC50   MIC90 
      
     S      I      R
 
*Ampicillin                                  202(100)          ≤2  16  ≥ 32        ≥ 32         ≥32                 
Amoxicillin/Clavulanic acid        64(31.7)          ≤2  16  ≥ 32        ≥ 32         ≥32                      
*Piperacillin                                 202(100)          ≤4 32-64 ≥ 128   ≥128      ≥128                                  
Piperacillin/Tazobactam              106(52.5)         ≤4  32 ≥128        ≥128      ≥128                     
*Cefazolin                                    202(100)          ≤4  16 ≥ 64         ≥ 64       ≥ 64                          
Cefoxitin                                       36(17.9)           ≤4 16 ≥ 64          32           ≥ 64              
*Cefotaxime                                 202(100)          ≤1 16 ≥ 64          ≥ 64       ≥ 64           
*Ceftazidime                                202(100)          ≤1 16 ≥ 64          16           ≥64 
*Cefepime                                    202(100)          ≤1 16 ≥ 64          2               32 
Imipenem                                     2(1.0)                ≤1   8  ≥ 16          ≤1            ≤1     
Amikacin                                     1(0.5)                 ≤2  32 ≥ 64         ≥64         ≥64         
Gentamicin                                  166(82.2)           ≤1   8  ≥ 16         ≥16         ≥16          
Ciprofloxacin                              161(79.7)           ≤0.25 2  ≥ 4         ≥ 4          ≥ 4                                                        
Norfloxacin                                 160(79.2)           ≤0.5  8 ≥ 16         ≥16        ≥16                                                            
Tetracycline                                 143(70.8)           ≤1   8  ≥  16        ≥16        ≥16                                                  
Nitrofurantoin                              94(46.5)            ≤16  64 ≥512       256        ≥512                  
Trimethoprim/Sulfamethoxazole 196(97.0)          ≤20  80 ≥320       ≥320       ≥320                                             
 
MIC50: MIC at which 50% of the ESBL-phenotypes were resistant to a particular antimicrobial agent        
MIC90: MIC at which 90% of the ESBL-phenotypes were resistant to a particular antimicrobial agent                                 
*All Penicillins and Cephalosporins are considered resistant to ESBL producers according to CLSI. 
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This current work sought to determine the occurrence of ESBLs in clinical isolates and their antimicrobial 
sensitivity profile. Of the 400 total bacterial isolates, 202 (50.5%) were ESBL producers of which 129 (73.7%) 
of the 175 K. pneumoniae and 73 (32.4%) of the 225 E. coli isolates were ESBL producers. 
Similar work by Feglo (2013) also reported that of the 405 clinical isolates screened at Komfo Anokye Teaching 
Hospital, Kumasi, Ghana, 234(57.8%) were ESBL producers.  
This is no different from the work published by Olysegun and colleagues in 2006 which observed 50% ESBL 
production rate in clinical isolates studied from northwestern Nigeria.  Kesah and Odugbemi (2002) reported 
more than 40% ESBL production among Enterobacteriaceae isolates in Lagos, Nigeria. This was collaborated 
by Aibinu and colleagues in 2003 by reporting 42% Enterobacter-producing ESBL organisms in clinical isolates 
of from Lagos, Nigeria. 
It may seem that the rate of ESBL-producing bacteria is assuming alarming rates in Ghana and West Africa. 
These infections may be either hospital-acquired or community-acquired ESBL-producers. The high prevalence 
of ESBL-producers may be attributed to prolong hospital admission and indiscriminate antibiotic exposure 
especially to extended-spectrum beta-lactam antibiotics used for the treatment of blood, urinary tract infections 
and other infectious diseases. This exerts antibiotic selective pressure for the emergence of ESBL-producing 
organisms in the population. Since extended spectrum beta-lactamases are plasmid mediated, the genes encoding 
these enzymes are easily transferable among other bacteria population thereby increasing the occurrence of 
ESBL-producing organisms. Nosocomial infections occur through the transmission of ESBL-producing 
organisms via the hands of hospital staff (Paterson and Bonomo, 2005).   
However, other published works in Central, Northern and Southern Africa suggest lower occurrence rates of 
ESBL-producing bacteria. Thirty-one (12%) of Enterobacteriaceae strains isolated from 259 patients at the 
Yaounde Central Hospital in Cameroon were shown to be positive for ESBLs (Gangoué-Piéboji et al., 2005). In 
Tanzania, Blomberg and colleagues (2005) reported that 15% of 126 enterobacteria isolates studied were ESBL-
producing E. coli and Klebsiella species. Bouchillon and colleagues (2004) have documented ESBL prevalence 
of 38.5% in Egypt. It has been reported that 36.1% of K. pneumoniae isolates collected in a single South African 
hospital in 1998 and 1999 were ESBL producers (Bell, et al., 2002).  
It can be inferred from the results in table 2 that K. pneumoniae isolates produced more ESBLs than E. coli 
isolates. This is collaborated by the work of Adu-Sarkodie (2010) which reported that ESBL has been isolated 
from 50.3% Klebsiella and 49.7% E. coli in Komfo Anokye Teaching Hospital, Kumasi. Infections emanating 
from K. pneumoniae isolates include urinary tract infection, pneumonia, bacteremia, thrombophlebitis, 
cholecystitis, upper respiratory tract infection, wound infection, osteomyelitis, meningitis (Umeh and Berkowitz, 
2009) and nosocomial infections (Falagas and  Karageorgopoulos, 2009). Cephalosporins are recommended for 
the treatment of most of these Klebsiellae infections (Brooks et al., 2004). The increase in prevalence of these 
infectious diseases may lead to a corresponding indiscriminate increase in cephalosporin exposure either through 
prescription or over-the-counter sales. The indiscrete use of extended-spectrum cephalosporins may then lead to 
selective pressure resulting from genetic mutation in favour of ESBL-producing K. pneumoniae. 
ESBLs are not active against cephamycins as demonstrated in table 3 which indicated that 73.8% of cefoxitin 
were susceptible to ESBL-producing isolates with MIC50 and MIC90 being ≤4µg/ml and 8µg/ml respectively. 
However, it has been reported that ESBL-producing strains can become resistant to cephamycins in vivo due to 
the loss of an outer membrane porin protein (Pangon et al, 1989).  
This present work recorded high non-β-lactam resistant to ESBL-producing E. coli and K. pneumoniae. 
Gentamicin, ciprofloxacin, norfloxacin, tetracycline and trimethoprim/sulfamethoxazole indicated 82.2%, 
79.7%, 79.2%, 70.8% and 97% resistant rates to ESBL producers. However, the resistant rates for amikacin 
(0.5%), imipenem (1%) and nitrofurantoin (46.5%) were slightly lower. This confirms the work of Adu-Sarkodie 
(2010) who indicated that the resistance prevalence of ciprofloxacin, norfloxacin, gentamicin, chloramphenicol, 
tetracycline, cotrimoxazole, amikacin, nitrofurantoin and imipenem were 56.73%, 79.41%, 81.43%, 90.00%, 
94.23%, 96.30% 20.00%, 19.7% and 0.00% respectively.  
A study by Aibinu and colleagues (2003) in hospitals in Lagos reported significant co-resistance of 75%, 89%, 
63% and 100% to ciprofloxacin, streptomycin, amikacin and trimethoprim-sulfamethoxazole respectively. 
However, their reported resistance rated for amikacin (63%) contradicted the outcome in this present work. In 
contrast, Olysegun and others did not report any antibiotic resistance genes reportedly associated with ESBLs on 
plasmids of ESBL-producing  
K. pneumoniae in Northwestern Nigeria (Olysegun et al., 2006). This may reflect diagnostic challenges of 
ESBLs in ESBL-associated antibiotic resistance prevalence. 
As recommended by CLSI (2006), all penicillins and cephasporins were considered to be resistant to ESBL 
producers as indicated in figure 2.  However, analysis of the MIC breakpoints of the cephalosporins 
demonstrated that 2.5%, 2.5%, 13.4% and 75.3% of cefazolin, cefotaxime, ceftazidime and cefepime showed in 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.3, No.12, 2013 
 
81 
vitro susceptibility to the ESBL producers as shown in table 4.  This shows that in vitro susceptibility of third 
and fourth generation cephalosporins to ESBL producers and their subsequent use for treatment may lead to 
therapeutic failure if no ESBL screening tests are performed. In a randomized trial of cefepime and imipenem, 
clinical response for infections with ESBL-producing organisms was 100% in patients treated with imipenem but 
only 69% in patients treated with cefepime (Yuan, et al., 1998). Yu and colleagues (2002) have observed that 
cefepime resistance may be more frequent in strains which produce ESBLs.  
Oteo and colleagues (2010) recommended the treatment of severe ESBL-producing E. coli infections to include 
the use of carbapenems, amikacin, tigecycline, and beta-lactam/beta-lactamase inhibitor combinations. For 
urinary tract infections, fosfomycin and nitrofurantoin could be useful. Results from this work support some 
aspect of this assertion especially for imipenem, amikacin and nitrofurantoin. However, amoxacillin/clavulanic 
acid and piperacillin/tazobactam recorded resistant rates of 31.7% (MIC50 and MIC90 is ≥32µg/ml) and 52.5% 
(MIC50 and MIC90 is ≥128µg/ml) respectively. 
Fluoroquinolones used to be regarded as the treatment of choice for complicated urinary tract infections due to 
ESBL-producing organisms (Paterson and Bonomo, 2005). Unfortunately, increasing in vitro resistance of ESBL 
producers to fluoroquinolones will limit the use of these antibiotics for treating ESBL-producing infections as 
demonstrated in figure 2 with 79.7% and 79.2% resistant rates for ciprofloxacin and norfloxacin respectively.  
 
5.0 Conclusion 
The findings of this study suggests that there are high rates 202(50.5%) of ESBL-producing E. coli and K. 
pneumonaie in Accra and  K. pneumonaie produces more extended spectrum beta-lactamases than E. coli 
isolates. The present work also established significant antimicrobial resistance among most of the non-β-lactam 
antibiotics such as ciprofloxacin, norfloxacin, gentamicin, tetracycline and trimethoprim/sulfamethoxazole. The 
outcome of this work recommends imipenem and amikacin as the drug of choice for treating infectious diseases 
caused by ESBL-producing organisms. Though nitrofurantoin may be considered in urinary tract infections, 
amoxicillin/clavulanic acid and piperacillin/tazobactam may not be good choice for treating infections resulting 
from ESBL producers. 
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